April 24, 2026

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...

The ASCO Post

April 24, 2026

Ulrich Steidl, MD, PhD, Named Director of Montefiore Einstein Comprehensive Cancer Center

An international leader in blood cancer and stem cell research has been named Director of the Montefiore Einstein Comprehensive Cancer Center and Vice President of Cancer Medicine at Montefiore Einste...

The ASCO Post

April 24, 2026

POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy

For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, pres...

The ASCO Post

April 23, 2026

ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma

The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing data sets surrounding T-cell–redirecting therapies in relapsed or refractory multiple...

The ASCO Post

April 23, 2026

Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

As reported in The Lancet by Lorusso et al, the phase III ROSELLA trial has shown an improvement in overall survival with the addition of relacorilant to nab-paclitaxel in patients with platinum-resis...

The ASCO Post

April 23, 2026

Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

In a Chinese phase II trial (EC-CRT-002) reported in the Journal of Clinical Oncology, Chen et al found that the addition of tislelizumab without maintenance cycles to induction chemotherapy and concu...

The ASCO Post

April 23, 2026

Perioperative Pembrolizumab in Localized Colorectal Cancer With dMMR/MSI

In a French phase II study (IMHOTEP) reported in the Journal of Clinical Oncology, de la Fouchardière et al found that perioperative pembrolizumab was active in previously untreated resectable localiz...

The ASCO Post

April 22, 2026

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker for angioimmunoblastic T-cell lymphoma, a rare subtype of non-H...

The ASCO Post

April 22, 2026

Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma

A population of patients with highly refractory follicular lymphoma achieved long-standing responses with few significant adverse events from odronextamab monotherapy, according to findings of the ELM...

The ASCO Post

April 22, 2026

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed...

The ASCO Post